Immune thrombocytopenia is a rare autoimmune disorder with associated bleeding risk and fatigue. Recommended first-line treatment for immune thrombocytopenia is high-dose glucocorticoids, but side ...
Please provide your email address to receive an email when new articles are posted on . Mycophenolate mofetil outperformed methotrexate, steroids and other immunosuppressives in diffuse cutaneous SSc ...
Purpose: The pharmacology, pharmacokinetics, drug interactions, clinical efficacy, adverse effects, monitoring, and dosage and administration of enteric-coated (EC) mycophenolate sodium are reviewed.
Researchers conducted a retrospective analysis of 1435 patients with limited cutaneous SSc from the Italian SPRING registry to assess the purpose of starting mycophenolate mofetil treatment and its ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients treated with mycophenolate mofetil were more ...
Maintenance therapy, often with azathioprine or mycophenolate mofetil, is required to consolidate remission and prevent relapse after the initial control of lupus nephritis. We carried out a 36-month, ...
Credit: Azurity Pharmaceuticals. Myhibbin is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection. Myhibbin is expected to be commercially available in the second ...
Discover comprehensive details about Mycophenolate Mofetil, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated ...
The use of mycophenolate mofetil (MMF) for prophylaxis of aGVHD and/or for treatment of acute or chronic GVHD is increasing. However, the benefit of MMF as an alternative to commonly used ...
A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis. A ...
In a new analysis of the BLISS LN trial, researchers added Belimumab (Benlysta) to Mycophenolate (MMF), the standard of care treatment for lupus nephritis, (LN, lupus-related kidney disease) and found ...
Triple-drug immunosuppression regimens including mycophenolate mofetil, taken for ≥6 months are associated with reduced rates of LAR; further studies are needed to define optimal immunosuppression ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results